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Serum Lipid Levels and the Risk of Venous Thrombosis
Carine J.M. Doggen, Nicholas L. Smith, Rozenn N. Lemaitre, Susan R. Heckbert,
Frits R. Rosendaal, Bruce M. Psaty
Objective—Lipids, through effects on the coagulation and fibrinolytic systems, may contribute to the development of
venous thrombosis. This association has been investigated in a few studies, with conflicting results.
Methods and Results—We conducted a population-based, case-control study at a health maintenance organization in
Washington State, to assess the association of serum lipid levels with the risk of venous thrombosis. Cases were 477
postmenopausal women with a first venous thrombosis during January 1995 through December 2001. Control subjects
(1986) were a random sample of postmenopausal women. Medical records, computerized pharmacy databases, and a
cancer registry served to collect data on lipid levels and risk factors for thrombosis. Total cholesterol levels were not
associated with venous thrombosis. Only high HDL cholesterol levels were associated with a decreased risk of venous
thrombosis after adjustment for hospitalization, malignancy, height and weight, postmenopausal hormone therapy, and
vascular disease (for high-density lipoprotein [HDL] cholesterol levels 1.79 mmol/L versus those 1.79 mmol/L;
odds ratio [OR], 0.71; 95% confidence interval [CI], 0.52 to 0.97). In contrast, elevated triglyceride levels were
associated with an increased risk (OR, 2.13; 95% CI, 1.34 to 3.37) for women with triglyceride levels 1.05 mmol/L
compared with women with lower levels.
Conclusion—Elevated triglyceride levels were associated with a doubling of risk of venous thrombosis in postmenopausal
women, whereas elevated HDL cholesterol levels were associated with a decreased risk. (Arterioscler Thromb Vasc
Biol. 2004;24:1970-1975.)
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Venous thrombosis, including deep vein thrombosis andpulmonary embolism, is a serious and potentially fatal
event.1 The average annual incidence is 1 to 3 per 1000 and
affects young and old, regardless of gender.2,3 Risk factors for
venous thrombosis may be genetic or acquired. Several
abnormalities of the coagulation system increase the risk of
thrombosis, such as factor V Leiden, the prothrombin 20210
G3A mutation, and high levels of procoagulant factors, for
example, factor II, factor VIII, factor IX, and factor XI.
Acquired risk factors classically are those associated with
immobilization, such as surgery, trauma, malignancy, and
pregnancy.4 However, there are still many patients with
venous thrombosis in whom no risk factor can be identified.
Elevated total serum cholesterol, elevated low-density-
lipoprotein (LDL) cholesterol, and low high-density-
lipoprotein (HDL) cholesterol are all well-established risk
factors for atherothrombotic disorders.5 Besides their strong
effects on atherogenesis, lipids and lipoproteins could influ-
ence hemostasis by modulating the expression and function
of procoagulant, fibrinolytic, and rheological factors.6 Tri-
glycerides, for example, seem to increase factor VII levels,
plasminogen activator inhibitor (PAI-1) levels, and blood
viscosity. LDL promotes platelet activation and tissue factor
expression. HDL has anti-atherothrombotic properties that
may result from inhibition of platelet aggregation, reduction
of viscosity, suppression of tissue factor activity, and PAI-1
activity levels, and enhancement of inactivation of factor Va
by activated protein C.7 Because of these possible biological
effects on the hemostatic system, lipids may also contribute to
the development of venous thrombosis.
The associations of venous thrombosis incidence with total
serum cholesterol, LDL and HDL cholesterol, as well as
triglyceride levels have been investigated in only a few
studies, and the results are inconsistent.8 We investigated the
association of total cholesterol, HDL cholesterol, and triglyc-
eride levels with the risk of incident venous thrombosis




The setting for this population-based, case-control study was Group
Health Cooperative (GHC), a large health maintenance organization
based in western Washington State, serving 400 000 members. The
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study was reviewed and approved by the human subjects review
committee at GHC.
Study Subjects, Eligibility, and Index Dates
Case subjects were all postmenopausal women aged 30 to 89 years
who had a first fatal or nonfatal venous thrombosis between January
1, 1995 and December 31, 2001. Potential cases were identified from
5 sources: (1) computerized Group Health hospital discharge rec-
ords; (2) Washington State death registry files; (3) billing records for
GHC members who received medical care or services from non-
GHC providers; (4) computerized GHC outpatient pharmacy files
indicating use of low-molecular-weight heparin; and (5) anticoagu-
lation treatment programs for GHC members treated for venous
thrombosis as outpatients. Control subjects were a random sample of
postmenopausal female GHC members sampled from the GHC
computerized enrollment files. Control subjects were identified from
a parallel ongoing case-control study of risk factors for myocardial
infarction, and were frequency matched on age, calendar year of
identification, and treated hypertension status to myocardial infarc-
tion cases.9 From this stratified sample of control subjects, those who
met the same eligibility criteria as the venous thrombosis cases and
did not have a venous thrombosis before their index dates were
included. We excluded women with chronic liver disease (n19),
those without a total cholesterol measurement before their index date
(n189), women with extreme lipid values (n2), women using
lipid-lowering drugs (n220), and women without a measurement of
weight and height (n11).
We identified 477 postmenopausal women with a venous throm-
bosis. Deep vein thrombosis in the leg and pulmonary embolism
were objectively verified with a venogram, Doppler or duplex study,
a pulmonary angiogram, lung scan with a high probability, or a
computer tomography scan in 94% of all cases. Of the remaining 28
women, 15 died before any diagnostic test or treatment could be
started, and 12 women were treated with coumarin derivatives or had
a vena cava filter after the diagnosis of venous thrombosis was
clinically made. Women who had a thrombosis in the arm because of
an indwelling vascular catheter or shunt were excluded.
All subjects had an index date. The index date for cases was the
date of their first venous thrombosis, and the index date for control
subjects was a computer-generated random date during the year for
which they were selected as control subjects.
Data Collection
Ambulatory medical records were used to determine eligibility and
to ascertain demographic and behavioral risk factors, medical con-
ditions, and lipid levels before the index date. This approach ensured
comparability between case and control subjects in the assessment of
eligibility criteria and risk factors. Abstraction of the information
from the medical records was performed by trained research assis-
tants who were not blinded to case-control status, but were unaware
of the research question. The GHC computerized pharmacy database
was used to assess current use of lipid-lowering drugs and postmeno-
pausal hormone therapy before the index date as described in
previous publications.10,11 The GHC cancer registry, which is de-
rived from the Surveillance, Epidemiology, and End Results (SEER)
registry, was used to retrieve information on malignancies.12 Previ-
ous hospitalization and fracture data were collected from GHC
inpatient and outpatient files using International Classification of
Diseases, 9th revision, Clinical Modification codes and were limited
to events that occurred within 90 days before the index date.
We collected information from the medical record before the
index date on postmenopausal status, weight and height, vascular
procedures, medical conditions such as chronic liver disease, hyper-
tension, and vascular disease, and lipid levels. Women were consid-
ered to be postmenopausal if ovarian function ceased because of
either natural menopause 6 months before the index date or
bilateral oophorectomy before natural menopause. Women aged 55
years or older for whom menopausal status at the index date was
unclear were assumed to be postmenopausal. Body mass index was
obtained by dividing weight in kilograms by the square of height in
meters. Vascular procedures included coronary artery bypass grafts,
coronary angioplasty, carotid endarterectomy, bypass grafting, and
angioplasty of the peripheral vessels. We considered women to be
hypertensive if they were pharmacologically treated for hyperten-
sion. Vascular disease was defined as a history of myocardial
infarction, angina pectoris, stroke, transient ischemic attack, or
claudication. Women with malignancies included those with a
history of cancer and those with cancer diagnosed within 3 months
after the index date. The most recent levels of total cholesterol, HDL
cholesterol, and triglycerides as recorded in the medical records
before index date were used in the analyses. The GHC primary
prevention guidelines for hyperlipidemia use the ratio of total
cholesterol to HDL cholesterol as the preferred method of assessing
risk. As a result of this policy, fasting lipid tests that include
triglycerides, which may be ordered at the discretion of the physi-
cian, are available for only a subset of those with total and HDL
cholesterol measurements.
Statistical Analyses
2 Tests for categorical variables and Student t test or analyses of
variance for continuous variables were used to assess differences
between cases and control subjects. All probability values represent
2-sided tests. Mean values are presented with their range or standard
deviation (SD). Because triglyceride levels were skewed, ln-
transformed values were used to test differences by using the t test.
Quartiles were defined on the basis of the distribution of lipid levels
among control subjects. The lowest quartiles were used as reference
categories for calculating odds ratios (OR). Unconditional logistic
regression analysis was used to adjust for age, index year, and
hypertension, as well as for potential confounders. The 95% confi-
dence intervals (CI) for the adjusted ORs were calculated using the
standard errors of the coefficients estimated by maximum likelihood
methods. In models that used continuous measures of lipid levels,
each measure was divided by its SD in control subjects to facilitate
comparison among total cholesterol, HDL cholesterol, and triglyc-
eride levels. Statistical analyses were performed using STATA 8.0
(Stata Corp).
Results
Eligible postmenopausal women (477) had a first fatal
(n26) or nonfatal (n451) venous thrombosis diagnosed;
340 (71%) had deep vein thrombosis, 53 (11%) had pulmo-
nary embolism, and 84 (18%) had both. We identified 1986
eligible control subjects among postmenopausal female GHC
members. Characteristics of women with a first venous
thrombosis and control subjects are shown in Table 1. Mean
ages of cases and control subjects were, respectively, 70.9
(range, 42.0 to 89.8) and 69.0 (range, 40.2 to 89.9) years. A
larger proportion of cases than control subjects had a hospi-
talization and fracture within 3 months before the index date,
as well as a history of malignancy and vascular disease.
In Table 2, the association between total cholesterol, HDL
cholesterol levels, and the risk of venous thrombosis is
presented for continuous measures and for quartiles. No
differences in mean total cholesterol level were identified
between cases and control subjects (P0.77). After adjust-
ment for the matching factors of age, index year, and treated
hypertension, SD change of 1.02 mmol/L in total cholesterol
level was not associated with the risk of venous thrombosis
(OR, 1.02; 95% CI, 0.92 to 1.13), which is supported by the
analysis using quartiles. The OR estimate per SD increased
slightly after further adjustment for hospitalization, malig-
nancy, weight, height, postmenopausal hormone therapy, and
vascular disease (OR, 1.06; 95% CI, 0.95 to 1.19). Further
adjustment for fractures, vascular procedures, race, and re-
centness of measurement did not affect the estimate.
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For women for whom HDL cholesterol levels were available,
HDL cholesterol levels were lower among 450 cases compared
with 1913 control subjects, respectively: 1.48 (SD 0.44) mmol/L
and 1.53 (SD 0.42) mmol/L (P0.02). Elevated HDL choles-
terol was associated with a decreased risk of venous thrombosis
after adjustment for age, index year, and treated hypertension
(OR per SD change in HDL [0.42 mmol/L] 0.81; 95% CI, 0.73
to 0.91). The estimated decrease in risk was attenuated after
further adjustments were made for hospitalization, malignancy,
weight, height, postmenopausal hormone therapy, and vascular
disease (OR, 0.88 per SD change; 95% CI, 0.78 to 1.00). Further
adjustments did not change the OR. The analysis by quartiles
suggested only a decreased risk for persons with relatively high
HDL levels, which again was less pronounced after adjustments
were made (ORs corresponding to quartiles of increasing HDL:
1, 1.03, 0.98, 0.71). The risk of venous thrombosis associated
with HDL cholesterol levels 1.79 mmol/L was estimated to be
decreased by 29% relative to HDL cholesterol levels
1.79 mmol/L (adjusted OR, 0.71; 95% CI, 0.52 to 0.97).
Values of all 3 lipid levels, total cholesterol, HDL choles-
terol, and triglyceride levels, were available for 1357 women:
248 cases and 1109 control subjects (Table 3). In this group,
TABLE 1. Characteristics of Postmenopausal Women with a First Venous




Age, mean (SD*) years 70.9 (11.2) 69.0 (9.6)
Non-white, % 6.1 12.5 0.001
Time enrolled in GHC,† mean (SD) years 22.4 (12.7) 23.1 (11.6) 0.3
Postmenopausal hormone therapy, % 37.1 36.5 0.8
Body mass index, mean (SD) kg/m2 28.7 (7.9) 27.8 (6.3) 0.01
Hospitalization in prior 3 months, % 31.2 2.2 0.001
Major fracture in prior 3 months, % 5.2 0.9 0.001
Malignancy, % 35.6 12.2 0.001
Vascular disease,‡ % 31.5 19.8 0.001
Vascular procedures,§ % 1.0 0.1 0.001
*Standard deviation.
†Group Health Cooperative
‡History of myocardial infarction, angina pectoris, stroke, transient ischemic attack, or claudica-
tion.
§Coronary artery bypass grafts, coronary angioplasty, carotid endarterectomy, bypass grafting, or
angioplasty of the peripheral vessels.
TABLE 2. Total Cholesterol and HDL Cholesterol Levels and the Risk of Venous Thrombosis in
Postmenopausal Women
OR (95% CI)* OR (95% CI)†
Total cholesterol, mmol/l 477 cases 1986 control subjects
Mean (SD) 6.03 (1.11) 6.02 (1.02)
Per SD increase 1.02 (0.92–1.13) 1.06 (0.95–1.19)
5.30 123 489 1 1
5.31–5.95 114 528 0.84 (0.63–1.12) 0.85 (0.61–1.18)
5.96–6.65 114 471 0.95 (0.71–1.27) 0.94 (0.68–1.32)
6.66 126 498 1.02 (0.77–1.36) 1.17 (0.84–1.62)
HDL cholesterol, mmol/l 450 Cases 1913 Control Subjects
Mean (SD) 1.48 (0.44) 1.53 (0.42)‡
Per SD increase 0.81 (0.73–0.91) 0.88 (0.78–1.00)
1.21 119 450 1 1
1.22–1.47 128 480 0.91 (0.69–1.22) 1.03 (0.74–1.44)
1.48–1.78 119 520 0.76 (0.57–1.02) 0.98 (0.69–1.37)
1.79 84 463 0.54 (0.40–0.75) 0.71 (0.49–1.03)
*Odds ratio adjusted for matching factors of age, index year, and treated hypertension.
†Odds ratio adjusted for matching factors, hospitalization, malignancy, weight, height, postmenopausal hormone
therapy, and vascular disease.
‡P0.05
To convert from mmol/l to mg/dl divide total and HDL cholesterol levels by 0.0259.
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total cholesterol levels were associated with an increased risk
of venous thrombosis (after adjustment for matching factors,
hospitalization, malignancy, weight, height, postmenopausal
hormone therapy, and vascular disease [OR, 1.17 per SD
change; 95% CI, 1.01 to 1.37]), in contrast to those in the
overall group. High HDL cholesterol levels were associated
with a decreased risk (adjusted OR, 0.86 per SD change; 95%
CI, 0.73 to 1.03) and limited to those with relatively high
HDL levels, findings similar to those in the overall group.
Mean triglyceride levels were higher among cases compared
with control subjects, respectively: 1.97 (SD 1.01) mmol/L
and 1.85 (SD 1.24 mmol/L; P0.01). The risk of venous
thrombosis was increased in women with elevated triglycer-
ide levels after adjustment for the matching factors (OR, 1.14
per SD change [1.24 mmol/L]; 95% CI, 1.00 to 1.30). The
ORs corresponding to quartiles of increasing triglycerides
were 1, 1.85, 2.62, and 2.25. Further adjustments changed
risks slightly. The risk of venous thrombosis associated with
triglyceride levels 1.05 mmol/L was estimated to be in-
creased by 2-fold relative to triglyceride levels
1.05 mmol/L (OR, 2.13; 95% CI, 1.34 to 3.37) after
adjustment for matching factors, hospitalization, malignancy,
weight, height, postmenopausal hormone therapy, and vascu-
lar disease. Adjustments for other factors had little effect on
the point estimate of the risk.
Similar results were found when only considering women
not receiving postmenopausal hormone therapy. Again, ele-
vated HDL cholesterol levels were associated with a de-
creased risk, especially high levels (OR, 0.87 per SD change;
95% CI, 0.74 to 1.02), ORs corresponding to quartiles of
increasing HDL (1, 1.16, 0.96, 0.70) adjusted for matching
factors, hospitalization, malignancy, weight, height, post-
menopausal hormone therapy, and vascular disease. Elevated
triglyceride levels were associated with an increased risk (OR
1.20 per SD change (95% CI 0.97 to 1.47), adjusted ORs
corresponding quartiles of increasing triglyceride levels 1,
2.69, 6.16 and 3.19).
Discussion
In this population-based case-control study, total cholesterol
levels overall were not associated with the risk of venous
thrombosis among postmenopausal women. High HDL cho-
lesterol levels were associated with a decrease in risk of
venous thrombosis. In contrast, elevated triglyceride levels
1.05 mmol/L were associated with a 2-fold increased risk of
venous thrombosis compared with women with lower levels.
Adjustment for potential confounders could only partly ex-
plain the associations.
Our findings of no association between total cholesterol
and the risk of venous thrombosis among postmenopausal
TABLE 3. Total Cholesterol, HDL Cholesterol and Triglyceride Levels and the Risk of Venous
Thrombosis in Postmenopausal Women who had a Triglyceride Level Measured
OR (95% CI)* OR (95% CI)†
Total cholesterol, mmol/l 248 cases 1109 control subjects
Mean (SD) 6.16 (1.17) 6.08 (1.05)
Per SD increase 1.10 (0.96–1.26) 1.17 (1.01–1.37)
5.30 53 260 1 1
5.31–5.95 63 296 1.07 (0.71–1.61) 1.21 (0.75–1.95)
5.96–6.65 57 244 1.15 (0.76–1.76) 1.18 (0.72–1.93)
6.66 75 309 1.27 (0.86–1.89) 1.59 (1.00–2.52)
HDL cholesterol, mmol/l
Mean (SD) 1.46 (0.44) 1.52 (0.42)
Per SD increase 0.83 (0.71–0.96) 0.86 (0.73–1.03)
1.21 70 282 1 1
1.22–1.47 63 275 0.86 (0.58–1.26) 0.96 (0.61–1.50)
1.48–1.78 71 291 0.90 (0.62–1.31) 1.09 (0.70–1.70)
1.79 44 261 0.57 (0.37–0.87) 0.68 (0.41–1.12)
Triglycerides, mmol/l
Mean (SD) 1.97 (1.01) 1.85 (1.24)‡
Per SD increase 1.14 (1.00–1.30) 1.10 (0.94–1.30)
1.05 35 284 1 1
1.06–1.58 61 271 1.85 (1.17–2.92) 1.79 (1.05–3.04)
1.59–2.28 85 280 2.62 (1.69–4.06) 2.66 (1.60–4.43)
2.29 67 274 2.25 (1.42–3.55) 1.94 (1.13–3.34)
*Odds ratio adjusted for matching factors of age, index year, and treated hypertension.
†Odds ratio adjusted for matching factors, hospitalization, malignancy, weight, height, postmenopausal hormone
therapy, and vascular disease.
‡P0.01.
To convert from mmol/l to mg/dl divide total and HDL cholesterol levels by 0.0259, and triglyceride levels by
0.0113.
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women overall are similar to the results of 2 prospective
follow-up studies13,14 and a small case-control study.15 How-
ever, findings of the prospective Framingham Heart Study
indicated that total cholesterol levels ascertained at entry
were significantly higher in women but not in men with
subsequent autopsy-confirmed major pulmonary embolism
compared with all participants, even after adjustment for
other risk factors.16 A Japanese case-control study reported
that hypercholesterolemia was associated with a higher risk
of deep vein thrombosis.17 Results of the prospective
follow-up “Study of Men born in 1913” indicated a reverse
association, with a lower total cholesterol level among those
developing a venous thromboembolic event,18 as did a small
case-control study.19
High HDL cholesterol levels were associated with a
decreased risk of venous thrombosis in our study among
postmenopausal women. Only 3 previous studies investigated
HDL cholesterol as a potential risk factor. One of these also
found lower HDL cholesterol levels among women with
venous thrombosis compared with control subjects,19 whereas
the other 2 studies did not find any association.14,15
Our results indicated an increased risk of venous thrombo-
sis with elevated triglyceride levels. Several previous studies
have reported a similar association,17,19,20 whereas other
studies found no association between triglyceride levels and
risk.14,15,18 Triglyceride levels showed an inverse correlation
with activated protein C ratio in women.21 Because a low
activated protein C ratio is known to increase the risk of
venous thrombosis,22 this might explain the association with
triglyceride levels as found in our study. Another possible
mechanism by which increased triglyceride levels may act is
elevation of factor VIIc levels,23 a possible risk factor for
venous thrombosis.24 Triglyceride levels are also associated
with increases in factor VIII, factor IX, and fibrinogen levels
in women,25 all of which are independent risk factors for
venous thrombosis.26,27 Unfortunately, we were unable to
measure (anti)coagulation factors in our study to clarify the
relationships.
Postmenopausal hormone therapy is known to increase
HDL cholesterol and triglyceride levels,28,29 and 35% of all
postmenopausal women in this study were using hormones.
However, the association between HDL cholesterol, triglyc-
erides, and venous thrombosis remained unchanged in the
subgroup of women not using postmenopausal hormones.
Several possible explanations for the different results
between studies exist. In a few studies measurements were
made on admission,15 after the event,19 or the timing of the
lipid measurement was not reported at all.17 Lipid measure-
ments need to be performed before the initial venous throm-
bosis, because lipid levels are known to decline in the
presence of acute vascular events.30 Second, persons using
lipid-lowering drugs should be excluded, because treatment
would influence the lipid levels. Several studies failed to
exclude these persons.13–18 Third, to avoid misclassification,
the diagnosis of venous thrombosis should be made objec-
tively by standardized methods instead of self-report. Other
possible explanations for the inconsistency of the findings
include the various ethnic origins of the populations and sex
or age differences.
The strengths of our study include the population-based
study design and the measurement of lipid levels before the
index date for cases with venous thrombosis and control
subjects. Although cases were identified after their event, the
assessment of lipid exposure and other risk factors before the
index date was based on information accrued in medical
records, in a cancer registry, and in a computerized pharmacy
database, thereby avoiding the possibility of information bias.
Almost all diagnoses of venous thrombosis were objectively
verified by standard diagnostic tests for deep vein thrombosis
and pulmonary embolism. Only 6% of all venous thromboses
were based solely on clinical grounds (including several
rapidly fatal events), hence minimizing misclassification.
Our study has a few limitations. Triglyceride levels were
not measured on 47% of our study population. Those women
who did have a triglyceride level measured had higher total
cholesterol levels, as might be expected. Another limitation
of our study is that several measurements were performed
years before the index date. If lipids have an immediate effect
on the risk of venous thrombosis, then we may have missed
such an association.
In conclusion, our findings suggest that elevated triglycer-
ide levels may be of importance in the development of venous
thrombosis in postmenopausal women, perhaps through their
effect on coagulation factors. Total cholesterol levels do not
appear to play a role, and elevated HDL cholesterol levels
were associated with a decreased risk of venous thrombosis.
Additional studies should be performed to confirm these
findings.
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